Lazard Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Sell
290,189
-710,256
-71% -$2.91M ﹤0.01% 1156
2025
Q4
$3.37M Buy
+1,000,445
New +$2.6M 0.01% 674
2024
Q2
Sell
-14,542
Closed -$126K 2336
2024
Q1
$126K Sell
14,542
-860
-6% -$10.4K ﹤0.01% 1459
2023
Q4
$176K Buy
15,402
+11
+0.1% +$109 ﹤0.01% 1436
2023
Q3
$148K Buy
15,391
+8,779
+133% +$86K ﹤0.01% 1487
2023
Q2
$70K Buy
6,612
+6,503
+5,966% +$69.9K ﹤0.01% 1717
2023
Q1
$1K Sell
109
-10,779
-99% -$121K ﹤0.01% 2241
2022
Q4
$134K Buy
+10,888
New +$124K ﹤0.01% 1413
2022
Q3
Sell
-10,900
Closed -$125K 2442
2022
Q2
$125K Buy
10,900
+4,630
+74% +$54.5K ﹤0.01% 1434
2022
Q1
$78K Buy
+6,270
New +$71.9K ﹤0.01% 1515
2021
Q4
Sell
-3,921
Closed -$51K 2375
2021
Q3
$51K Buy
+3,921
New +$50.7K ﹤0.01% 1678
2021
Q1
Sell
-77,200
Closed -$878K 1929
2020
Q4
$878K Buy
77,200
+35,821
+87% +$392K ﹤0.01% 911
2020
Q3
$372K Buy
+41,379
New +$411K ﹤0.01% 902
2020
Q2
Sell
-8,536
Closed -$86K 1696
2020
Q1
$86K Buy
8,536
+4,962
+139% +$58.3K ﹤0.01% 1029
2019
Q4
$47K Buy
3,574
+2,101
+143% +$23.2K ﹤0.01% 1072
2019
Q3
$12K Buy
+1,473
New +$14.3K ﹤0.01% 1261

Other funds holding IRWD

Lazard Asset Management's IRWD Position: Q1 2026 in Review

Lazard Asset Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 71% in Q1 2026, selling an estimated $2.91M and leaving 290,189 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Lazard Asset Management first reported a position in IRWD in Q3 2019 and has held it in 16 quarters since. The position peaked at $3.37M in Q4 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Lazard Asset Management held 290,189 shares of Ironwood Pharmaceuticals worth $1.02M as of Q1 2026.
  • Lazard Asset Management sold 710,256 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $2.91M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1156 holding.
  • Lazard Asset Management first reported a position in Ironwood Pharmaceuticals in Q3 2019 and has held it in 16 quarters since.
  • Lazard Asset Management's Ironwood Pharmaceuticals position peaked at $3.37M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.